Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.49 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25987817 | 0.86 | ACHE (0.49) | EPHX2KDM2BEPHX1ACHEMCHR1 | |
| SCHEMBL23389214 | 0.80 | EPHX2 (0.42) | EPHX2KDM2BEPHX1ACHEHRH3 | |
| SCHEMBL23389211 | 0.80 | EPHX2 (0.42) | EPHX2KDM2BEPHX1ACHEHRH3 | |
| SCHEMBL23419098 | 0.76 | HRH3 (0.56) | EPHX2ACHEMCHR1HRH3 | |
| SCHEMBL23881938 | 0.74 | SLC6A1 (0.43) | — | |
| SCHEMBL23881940 | 0.74 | SLC6A1 (0.43) | — | |
| SCHEMBL23573338 | 0.73 | EPHX2 (0.72) | EPHX2EPHX1POLB | |
| SCHEMBL25987834 | 0.73 | CTSL (0.48) | EPHX1HTR2A | |
| SCHEMBL23389106 | 0.72 | KMT2A (0.55) | EPHX2EPHX1POLB | |
| SCHEMBL23389107 | 0.72 | KMT2A (0.55) | EPHX2EPHX1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | EPHX2 3551/4885KDM2B 3814/4885EPHX1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.